[Cost-effectiveness of treatment of type 2 diabetes mellitus in México].
Diana L Pérez-LozanoVíctor Manuel Camarillo-NavaTarsila Elizabeth Juárez-ZepedaJosé Elpidio Andrade-PinedaDanae Pérez-LópezJorge Armando Reyes-PachecoZuley Margarita Lucho-GutiérrezLiliana Carmona-AparicioPublished in: Revista medica del Instituto Mexicano del Seguro Social (2023)
Metformin presented a better cost-effectiveness ratio in monotherapy, while in bitherapy it was the metformin/NPH insulin association.